Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 10/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | ABAT | P80404 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25596283 | 0.87 | ESR1 (0.55) | ESR1BLMESR2TAAR1SLC6A2 | |
| SCHEMBL25596196 | 0.76 | BLM (0.63) | ESR1BLMESR2TAAR1SLC6A2 | |
| SCHEMBL25596195 | 0.76 | BLM (0.63) | ESR1BLMESR2TAAR1SLC6A2 | |
| SCHEMBL22074778 | 0.76 | BLM (0.58) | ESR1BLMESR2TAAR1SLC6A2 | |
| SCHEMBL564410 | 0.76 | ESR1 (0.67) | ESR1BLMESR2TAAR1SLC6A2 | |
| SCHEMBL25596169 | 0.73 | ESR1 (0.57) | ESR1BLMESR2TAAR1SLC6A2 | |
| SCHEMBL9583933 | 0.71 | ESR1 (0.59) | ESR1BLMESR2TAAR1SLC6A2 | |
| SCHEMBL5329248 | 0.71 | ESR1 (0.64) | ESR1BLMESR2SLC6A2ABAT | |
| SCHEMBL25596280 | 0.71 | ESR1 (0.59) | ESR1BLMESR2TAAR1SLC6A2 | |
| SCHEMBL73405 | 0.71 | ESR1 (1.00) | ESR1BLMESR2SLC6A2ABAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | SENDA BIOSCIENCES INC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | COMT, SNCA, PARK7 | ESR1 4421/4885BLM 3756/4885ESR2 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.